Liao Dehua, Yu Lun, Shangguan Dangang, Zhang Yongchang, Xiao Bowen, Liu Ni, Yang Nong
Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Department of PET-CT Center, Chenzhou NO. 1 People's Hospital, Chenzhou, China.
Front Pharmacol. 2022 Jun 6;13:905947. doi: 10.3389/fphar.2022.905947. eCollection 2022.
Lung cancer is the leading cause of cancer-related deaths with high morbidity and mortality. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 85% of all cases. Fortunately, the development of molecular oncology provides a promising and effective therapeutic strategy for lung cancers, including specific gene mutations/translocations and immune checkpoints, with epidermal growth factor receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later as the targeted therapy and immune checkpoint inhibitors (ICIs) as immunotherapy. This review summarized the recent therapy advancements of TKIs and ICIs in NSCLC and focused on the clinical effect of combination or sequential treatment so as to provide the effective advice for the treatment of NSCLC.
肺癌是癌症相关死亡的主要原因，发病率和死亡率都很高。非小细胞肺癌（NSCLC）是最常见的肺癌类型，占所有病例的85%。幸运的是，分子肿瘤学的发展为肺癌提供了一种有前景且有效的治疗策略，包括特定的基因突变/易位和免疫检查点，首先是表皮生长因子受体（EGFR）常见突变，随后是间变性淋巴瘤激酶（ALK）易位作为靶向治疗，以及免疫检查点抑制剂（ICI）作为免疫治疗。本综述总结了NSCLC中酪氨酸激酶抑制剂（TKI）和ICI的最新治疗进展，并重点关注联合或序贯治疗的临床效果，以便为NSCLC的治疗提供有效的建议。
